Table 3.

Results of multivariable analysis when examining interaction between lipid levels, statin use and the development or progression of AMD compared to those with similar lipid levels and less <12 months statin use^*¥

	Development of Non- exudative AMD			Development of Exudative AMD			Progression from Non- exudative to Exudative AMD
Lipid Level in Beneficiaries with >1year statin use	Hazard Ratios	95% Confidence Intervals		Hazard Ratios	95% Confidence Intervals		Hazard Ratios	95% Confidence Intervals
Low HDL (<40)¥	1.04	0.95	1.13	0.89	0.72	1.09	0.88	0.66	1.17
Average HDL (40–59)	0.92†	0.86	0.99	1.02	0.88	1.18	0.90	0.74	1.10
Optimal HDL (≥60)	0.99	0.91	1.06	1.24†	1.04	1.47	1.96†	1.58	2.42
Optimal LDL (<100)	1.04	0.95	1.14	0.89	0.72	1.09	0.88	0.66	1.17
Near Optimal LDL (100–129)	1.11†	1.00	1.23	0.80	0.64	1.01	0.54†	0.40	0.73
Borderline High LDL (130–159)	1.01	0.87	1.16	0.51†	0.37	0.71	0.87	0.58	1.27
High to Very High LDL (≥160)	0.80†	0.64	0.99	1.49†	1.03	2.15	2.08†	1.29	3.36
Optimal TG (<150)	1.04	0.95	1.18	0.89	0.72	1.09	0.88	0.66	1.17
Borderline High TG (150–199)	1.06	0.95	1.18	2.09†	1.66	2.63	1.80†	1.27	2.54
High to Very High TG (≥200)	1.20†	1.09	1.33	1.34†	1.08	1.67	1.54†	1.14	2.08

^*Variables controlled for in multivariable analyses: age, sex, race, region of the country, education level, net worth, coagulopathies, skin cancer, iron deficiency anemia, blood loss anemia, renal disease, diabetes, hypertension, cerebrovascular accidents, myocardial infarct, congestive heart failure, peripheral vascular disease, obesity, hypotension, use of other lipid lowering medications, cataract, pseudophakia or aphakia, open angle glaucoma, diabetic eye disease

^¥Example of how this chart should be read: A beneficiary with >1 year of statin use and an HDL <40mg/dl had a 4% increased hazard of developing non-exudative AMD compared to a beneficiary with <1year of statin use and a HDL of <40mg/dl

^†p≤0.05